SRX Global completes senior secured debt investment in CERo up to $11.67M

SRx Health Solutions, Inc.

Note consolidates prior convertible notes totaling $5,666,108.77; additional advances up to $6,000,000 for $11,666,108.77 max.
Initial advance of $775,665 funded Aug 27, 2026 for working capital; 10% annual interest (24.99% default).
Maturity Oct 15, 2026; extendable up to four 30-day periods; secured by CERo subsidiary stock and CER-1236 assets, plus guarantee.
CER-1236 Phase 1 CERTAIN-T: six patients dosed, no DLTs in latest cohort; third cohort (1B cells/patient) expands to MDS and myelofibrosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.